Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Medarex/BMS drug combo shows durable response in melanoma
In the study, complete or partial responses in seven of 56 patients with metastatic melanoma showed durability ranging from four months to the longest still ongoing at over
In the study, complete or partial responses in seven of 56 patients with metastatic melanoma showed durability ranging from four months to the longest still ongoing at over
Novartis will be responsible for further development of AD 237 both as monotherapy and in combination with QAB149, its once-daily, long-acting beta2 agonist currently in phase II clinical
The findings, from a comparative clinical study on the effects of smoking on the pharmacokinetics of Tarceva (erlotinib) in healthy (non-cancer patients) smokers and non-smokers, built upon observations
The companies had previously entered into an agreement in June 2003 to develop an initial prescription steroid product for the US using one of Dow’s patented drug delivery
The chimeric hybrid analgesics are an invention of Chimeracom’s chief science officer, Dr Richard Kream, and the patent covers composition of matter for, and methods of treating pain
The trial will assess the safety of the formulation of BLP25 Liposome Vaccine (L-BLP25) that the companies expect to use in an upcoming phase III study. This formulation
Peninsula’s lead product candidate, doripenem, is a broad-spectrum antibiotic and a new member of the carbapenem class of beta-lactam antibiotics. Peninsula is currently evaluating doripenem in six phase
The vaccine, based on Vical’s proprietary DNA delivery technology, was co-developed at the National Institute of Allergy and Infectious Diseases’ (NIAID) Vaccine Research Center (VRC) and at Vical.
Forerunner Pharma Research Company (FPR) is set to commence operations from April 22, 2005. Established as a solution to meet the need, FPR, based in the Komaba Open
The pivotal study, which will be carried out under an FDA fast track designation, will include patients with the most common form of cutaneous T-cell lymphoma (CTCL), mycosis